Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
TET2 CRISPR Activation Plasmid (h): sc-400545-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- TET2 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- TET2 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by TET2 CRISPR Activation Plasmid (h) and TET2 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the TET2 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: TET2 Antibody (C-7): sc-398535
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TET2 CRISPR Activation Plasmid (h) | sc-400545-ACT | 20 µg | $397.00 | |||
TET2 CRISPR Activation Plasmid (h2) | sc-400545-ACT-2 | 20 µg | $397.00 |
Human TET2 encodes a Fe(II)/2-oxoglutarate–dependent dioxygenase that oxidizes 5-methylcytosine to 5-hydroxymethylcytosine and further derivatives, promoting active and passive DNA demethylation. Through regulation of enhancer and promoter methylation states, TET2 shapes transcriptional programs controlling hematopoietic differentiation, self-renewal, and immune cell lineage specification. TET2 function is integrated with epigenetic pathways involving chromatin modifiers and DNA repair-associated processing of oxidized cytosine bases, influencing genome-wide accessibility and gene expression stability. Dysregulation or mutation of TET2 is frequently associated with clonal hematopoiesis and myeloid malignancy biology, making it a key target for mechanistic studies of epigenetic remodeling in disease-relevant cell systems.
TET2 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous TET2 expression without altering the underlying DNA sequence.
TET2 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the TET2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the TET2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous TET2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native TET2 locus and enabling the study of TET2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of TET2 pathway restoration in tumor cells with silenced or reduced TET2 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.